Propella: Intramuscular abiraterone decanoate for metastatic prostate cancer PRL-02
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Propella Therapeutics Inc
Start Date
January 20, 2022
End Date
September 26, 2026
Administered By
Duke Cancer Institute
Awarded By
Propella Therapeutics Inc
Start Date
January 20, 2022
End Date
September 26, 2026